OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Innovative β-Lactam/β-Lactamase Inhibitor Combinations for Carbapenem-Resistant Gram-Negative Bacteria
Daniele Roberto Giacobbe, Matteo Bassetti
Future Microbiology (2022) Vol. 17, Iss. 6, pp. 393-396
Closed Access | Times Cited: 9

Showing 9 citing articles:

Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli
David M. Livermore, Shazad Mushtaq, Anna Vickers, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 5, pp. 106776-106776
Open Access | Times Cited: 26

Current and Emerging Treatment Options for Multidrug Resistant Escherichia coli Urosepsis: A Review
Mikaela M. Walker, Jason A. Roberts, Benjamin A. Rogers, et al.
Antibiotics (2022) Vol. 11, Iss. 12, pp. 1821-1821
Open Access | Times Cited: 27

Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades
Daniele Roberto Giacobbe, Vincenzo Di Pilato, Ilias Karaiskos, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 101-113
Open Access | Times Cited: 15

A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections
Maryam Safarpour-Dehkordi, Omid Chabok, Mohsen Asgari, et al.
Archives of Microbiology (2024) Vol. 206, Iss. 3
Closed Access | Times Cited: 1

Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?
Matteo Bassetti, Daniele Roberto Giacobbe
Med (2024) Vol. 5, Iss. 5, pp. 380-382
Closed Access | Times Cited: 1

Process Development and Scale-Up of the Novel β-Lactamase Inhibitor WCK 6395
Yasinalli Tamboli, Jaydeo T. Kilbile, Vikas Deshmukh, et al.
Organic Process Research & Development (2023) Vol. 27, Iss. 3, pp. 496-504
Closed Access | Times Cited: 2

Interpreting the results of rapid molecular diagnostic tests for carbapenem-resistant Enterobacterales infection: current clinical perspective while waiting for further evidence
Daniele Roberto Giacobbe, Vincenzo Di Pilato, Antonio Vena, et al.
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 7, pp. 583-590
Closed Access

Antibiotic treatment of critically ill patients with sepsis: From FK/FD to novel drugs
Maja Šurbatović, Aneta V. Perić, Goran Rakić, et al.
Galenika Medical Journal (2023) Vol. 2, Iss. 5, pp. 14-22
Closed Access | Times Cited: 1

Case series; Ceftazidime/avibactam for treating post-neurosurgical ventriculitis and meningitis due to Carbapenem-resistant Klebsiella pneumonia (CRKP)
Sajan Pandey, Peiwen Yao, Zhouqi Qian, et al.
Interdisciplinary Neurosurgery (2023) Vol. 34, pp. 101832-101832
Open Access | Times Cited: 1

Page 1

Scroll to top